Trial · NCT00819234
Results by group580
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 580
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| LS Mean Percent Change in Body Weight From Original Study DFA102 (NCT00673387) Baseline (Day 1) at Week 52 in Extension Study DFA102E - Evaluable Treatment Stable Population | Placebo - Stable | -2.68 | 95% Confidence Interval 2.170 | percentage of change in weight | |
| LS Mean Percent Change in Body Weight From Original Study DFA102 (NCT00673387) Baseline (Day 1) at Week 52 in Extension Study DFA102E - Evaluable Treatment Stable Population | Pramlintide 360 Mcg + Metreleptin 1.25 mg - Stable | -9.92 | 95% Confidence Interval 2.203 | percentage of change in weight | |
| LS Mean Percent Change in Body Weight From Original Study DFA102 (NCT00673387) Baseline (Day 1) at Week 52 in Extension Study DFA102E - Evaluable Treatment Stable Population | Pramlintide 360 Mcg + Metreleptin 2.5 mg - Stable | -9.24 | 95% Confidence Interval 1.944 | percentage of change in weight | |
| LS Mean Percent Change in Body Weight From Original Study DFA102 (NCT00673387) Baseline (Day 1) at Week 52 in Extension Study DFA102E - Evaluable Treatment Stable Population | Pramlintide 360 Mcg + Metreleptin 5.0 mg - Stable | -8.20 | 95% Confidence Interval 2.201 | percentage of change in weight | |
| LS Mean Absolute Change in Body Weight From Original Study Baseline (Day 1) at Weeks 12, 28, 36, 44, and 52 - Evaluable Treatment Stable Population | Placebo - Stable | Week 12 (original study) | -4.59 | 95% Confidence Interval -6.55 to -2.62 | kg |
| LS Mean Absolute Change in Body Weight From Original Study Baseline (Day 1) at Weeks 12, 28, 36, 44, and 52 - Evaluable Treatment Stable Population | Pramlintide 360 Mcg + Metreleptin 1.25 mg - Stable | Week 12 (original study) | -6.72 | 95% Confidence Interval -8.71 to -4.73 | kg |
| LS Mean Absolute Change in Body Weight From Original Study Baseline (Day 1) at Weeks 12, 28, 36, 44, and 52 - Evaluable Treatment Stable Population | Pramlintide 360 Mcg + Metreleptin 2.5 mg - Stable | Week 12 (original study) | -7.31 | 95% Confidence Interval -9.07 to -5.55 | kg |
| LS Mean Absolute Change in Body Weight From Original Study Baseline (Day 1) at Weeks 12, 28, 36, 44, and 52 - Evaluable Treatment Stable Population | Pramlintide 360 Mcg + Metreleptin 5.0 mg - Stable | Week 12 (original study) | -7.06 | 95% Confidence Interval -9.05 to -5.07 | kg |
| LS Mean Absolute Change in Body Weight From Original Study Baseline (Day 1) at Weeks 12, 28, 36, 44, and 52 - Evaluable Treatment Stable Population | Placebo - Stable | Week 28 (Baseline for Extension) | -3.70 | 95% Confidence Interval -6.74 to -0.66 | kg |
| LS Mean Absolute Change in Body Weight From Original Study Baseline (Day 1) at Weeks 12, 28, 36, 44, and 52 - Evaluable Treatment Stable Population | Pramlintide 360 Mcg + Metreleptin 1.25 mg - Stable | Week 28 (Baseline for Extension) | -8.63 | 95% Confidence Interval -11.72 to -5.55 | kg |
| LS Mean Absolute Change in Body Weight From Original Study Baseline (Day 1) at Weeks 12, 28, 36, 44, and 52 - Evaluable Treatment Stable Population | Pramlintide 360 Mcg + Metreleptin 2.5 mg - Stable | Week 28 (Baseline for Extension) | -9.91 | 95% Confidence Interval -12.64 to -7.19 | kg |
| LS Mean Absolute Change in Body Weight From Original Study Baseline (Day 1) at Weeks 12, 28, 36, 44, and 52 - Evaluable Treatment Stable Population | Pramlintide 360 Mcg + Metreleptin 5.0 mg - Stable | Week 28 (Baseline for Extension) | -9.46 | 95% Confidence Interval -12.55 to -6.38 | kg |
| LS Mean Absolute Change in Body Weight From Original Study Baseline (Day 1) at Weeks 12, 28, 36, 44, and 52 - Evaluable Treatment Stable Population | Placebo - Stable | Week 36 in Extension Study | -3.53 | 95% Confidence Interval -6.95 to -0.12 | kg |
| LS Mean Absolute Change in Body Weight From Original Study Baseline (Day 1) at Weeks 12, 28, 36, 44, and 52 - Evaluable Treatment Stable Population | Pramlintide 360 Mcg + Metreleptin 1.25 mg - Stable | Week 36 in Extension Study | -9.74 | 95% Confidence Interval -13.21 to -6.27 | kg |
| LS Mean Absolute Change in Body Weight From Original Study Baseline (Day 1) at Weeks 12, 28, 36, 44, and 52 - Evaluable Treatment Stable Population | Pramlintide 360 Mcg + Metreleptin 2.5 mg - Stable | Week 36 in Extension Study | -10.69 | 95% Confidence Interval -13.75 to -7.63 | kg |
| LS Mean Absolute Change in Body Weight From Original Study Baseline (Day 1) at Weeks 12, 28, 36, 44, and 52 - Evaluable Treatment Stable Population | Pramlintide 360 Mcg + Metreleptin 5.0 mg - Stable | Week 36 in Extension Study | -9.21 | 95% Confidence Interval -12.68 to -5.75 | kg |
| LS Mean Absolute Change in Body Weight From Original Study Baseline (Day 1) at Weeks 12, 28, 36, 44, and 52 - Evaluable Treatment Stable Population | Placebo - Stable | Week 44 in Extension Study | -3.10 | 95% Confidence Interval -6.82 to 0.63 | kg |
| LS Mean Absolute Change in Body Weight From Original Study Baseline (Day 1) at Weeks 12, 28, 36, 44, and 52 - Evaluable Treatment Stable Population | Pramlintide 360 Mcg + Metreleptin 1.25 mg - Stable | Week 44 in Extension Study | -9.38 | 95% Confidence Interval -13.16 to -5.60 | kg |
| LS Mean Absolute Change in Body Weight From Original Study Baseline (Day 1) at Weeks 12, 28, 36, 44, and 52 - Evaluable Treatment Stable Population | Pramlintide 360 Mcg + Metreleptin 2.5 mg - Stable | Week 44 in Extension Study | -10.00 | 95% Confidence Interval -13.33 to -6.66 | kg |
| LS Mean Absolute Change in Body Weight From Original Study Baseline (Day 1) at Weeks 12, 28, 36, 44, and 52 - Evaluable Treatment Stable Population | Pramlintide 360 Mcg + Metreleptin 5.0 mg - Stable | Week 44 in Extension Study | -8.60 | 95% Confidence Interval -12.38 to -4.82 | kg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00819234/results